The FDA approved a higher potency formulation of human rabies immune globulin (RIG). Beginning in May, RIG will provide a post-exposure prophylaxis (PEP) option that is easier for pharmacists and other providers to administer as well as potentially more tolerable and effective for patients.
“Most people who die of rabies don’t receive any prophylaxis,” said Charles Rupprecht, VMD, MS, PhD, an expert technical advisor on rabies for the Pan American Health